News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 5, 2024

Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Episodes in this series

Video 1 - "Conditions for Administering Bispecific Therapy"

EP. 1 Conditions for Administering Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 2 Navigating Barriers Which Inhibit Optimal Use of Bispecifics

Video 3 - "Key Decision Makers and Contributors Involved In Bispecific Administration"

EP. 3 Key Decision Makers and Contributors Involved In Bispecific Administration

Video 4 - "Pain Points In Bispecific Operationalization"

EP. 4 Pain Points In Bispecific Operationalization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 5 Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 6 Optimizing Bispecific Use Through EMR Utilization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 7 Best Practices For Uptake and Use of Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 8 Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 9 Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 10 Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 11 Protocol For Urgent and Around-the-Clock Bispecific Care

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 12 Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 13 Managed Care Considerations Within Bispecific Landscape

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 14 Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 15 Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 16 Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

Evolocumab Cuts Death Risk for a First Heart Attack or Stroke

Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD

FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia

NFL Dementia Deaths Often Miss Neurodegenerative Diagnosis